<DOC>
	<DOCNO>NCT00297947</DOCNO>
	<brief_summary>This study investigate safety efficacy quetiapine sub-optimally respond patient DSM-IV schizophrenia use double blind , randomize 12-week trial compare oral dos 1200 mg/d 600 mg/d quetiapine .</brief_summary>
	<brief_title>High Dose Quetiapine Treating Subjects With Treatment Refractory Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description>The study conduct two site : Manhattan Psychiatric Center ( MPC ) , Clinical Research Evaluation Facility Nathan S. Kline Institute Psychiatric Research/Rockland Psychiatric Center ( NKI ) . A total 60 patient enrol , 30 location . After screen period 1 week , patient enter open label , four-week quetiapine treatment period ( run-in phase ) , quetiapine titrate 600 mg PO daily adjunctive antipsychotic gradually taper discontinue . Other concomitant medication mood stabilizer maintain , dose stable precede 2 month . Patients respond quetiapine treatment 600 mg PO ( define reduction &lt; 15 % change Positive Negative Syndrome Scale ( PANSS ) total score start run-in end week 4 ) run-in phase , eligible enter double blind phase . Study baseline Day 7 Week 4 run-in phase . Patients qualify double-blind phase randomly assign either high dose 1200 mg quetiapine daily ( Group A ) 600 mg quetiapine ( Group B ) daily treat assign dose double blind fashion 8 week ( Week 1 Week 8 double blind phase ) . Measures extra-pyramidal side effect , psychopathology , safety conduct throughout trial .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . DSMIV criterion chronic schizophrenia schizoaffective disorder 2 . Suboptimal treatmentresponse 3 . Total score &gt; 60 Positive Negative Syndrome Scale ( PANSS ) baseline runin phase baseline double blind phase 4 . Age 1864 year old 5 . Signed informed consent 6 . Patient good general medical health Exclusion criterion : 1 . History failure respond 400 mg/day clozapine 8 contiguous week 2 . History failure respond quetiapine treatment dosages &gt; 1200 mg daily 6 contiguous week 3 . History quetiapine intolerance ( e.g. , clinically significant leukopenia agranulocytosis , severe dystonic reaction ) 4 . Significant recent history violence suicidal activity , require &gt; 4 episode PRN antiagitation medication per week 5 . Mental retardation 6 . Depot antipsychotic within 30 day randomization 7 . Significant medical illness require frequent dose adjustment medication change Clozapine nonresponders explicitly exclude , would unlikely show response study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>quetiapine</keyword>
	<keyword>schizoaffective disorder</keyword>
</DOC>